Combining two serotonergic psychedelics in the same session or on consecutive days raises the same interaction risks this site's medication-safety guide covers — and no clinical trial has studied the combination.
People preparing for a psilocybin session sometimes ask whether it is safe to also use MDMA — either in the same sitting or on a nearby day. The question surfaces often enough in psychedelic-access communities that facilitators and guides address it directly with clients, usually to discourage it rather than explain how to do it.
This guide explains the pharmacology behind that caution and what the research record does and does not say. It is not instructions for combining the two substances, and neither substance is legal for unsupervised recreational use in the United States — MDMA and psilocybin are both Schedule I federally. Supervised access to either exists only through FDA clinical trials, Oregon's Measure 109 or Colorado's Prop 122 Natural Medicine program (psilocybin only), or other research settings.
MDMA works primarily by triggering a large release of serotonin (along with dopamine and norepinephrine). Psilocybin — after the body converts it to psilocin — acts on the same serotonin 2A (5-HT2A) receptors that classic psychedelics use. Taking both substances close together means stacking two different mechanisms that both raise serotonin activity, rather than one.
That is the same mechanism behind the SSRI, MAOI, and ayahuasca interactions documented on this site's psychedelic medication safety guide — the risk is serotonin syndrome, a spectrum that runs from mild agitation and sweating to, in rare severe cases, high fever and muscle rigidity. The published reviews on psychedelic drug-drug interactions (cited below) document this mechanism for psychedelics combined with serotonergic medications; they do not report data on two psychedelics combined with each other, because that combination has not been studied in a controlled setting.
MDMA and psilocybin are each the subject of active FDA drug development — MDMA-assisted therapy for PTSD and psilocybin therapy for depression are studied as standalone treatments, on their own dosing and screening protocols. Neither the MAPS MDMA-assisted therapy treatment manual nor any published psilocybin trial protocol administers the two substances together.
That means there is no clinical safety data, no established washout window, and no studied dose ratio for combining them — unlike, say, the SSRI washout windows clinical trials do publish for psilocybin alone. Any claim about a "safe" way to combine MDMA and psilocybin would be going beyond what the evidence supports, which is why this guide does not offer one.
On the Psychedelic Passage podcast, a listener asked in a Q&A session how important it is to take MDMA the day before psilocybin. The host and a facilitator both said they would caution against treating that as a fixed protocol. Their reasoning: MDMA's serotonin release depletes stores the body needs to replenish, so stacking it with psilocybin the next day compounds the serotonergic load and adds recovery time and fatigue on top of it.
That is one practitioner's view from a single episode, not a clinical finding, and it lines up with the wider caution clinical programs already apply. Most screen out unsanctioned drug combinations before a session, and reputable retreats ask clients to disclose everything they have taken and when. The right course is to raise the question with a supervising clinician or facilitator before either session, rather than follow a fixed spacing rule on your own — the correct answer, if there is one, depends on a person's health history.
Serotonin syndrome symptoms exist on a spectrum. Early signs include agitation, restlessness, sweating, and tremor. More severe signs include high fever, muscle rigidity, rapid heart rate, and confusion. This site's dedicated serotonin syndrome warning signs guide covers the full early-to-severe progression and the Hunter Serotonin Toxicity Criteria clinicians use to recognize it.
There is no established safe protocol. Both substances are serotonergic — MDMA releases serotonin and psilocybin acts on serotonin 2A receptors — so combining them stacks the same interaction risk covered on this site's psychedelic medication safety guide. No registered clinical trial has studied the combination, so there is no clinical safety data, washout window, or studied dose ratio to point to.
There is no clinical answer, but on the Psychedelic Passage podcast, a facilitator answering a listener's Q&A said they would caution against it, since MDMA depletes serotonin stores the body needs to replenish and stacking it with psilocybin the next day adds serotonergic and cardiovascular load. That is one practitioner's anecdotal view, not a studied finding — discuss timing with a supervising clinician or facilitator rather than following a fixed rule.
Early signs include agitation, restlessness, sweating, and tremor. More severe signs include high fever, muscle rigidity, rapid heart rate, and confusion. High fever, muscle rigidity, seizure activity, or loss of consciousness is a medical emergency — call 911. See this site's serotonin syndrome warning signs guide for the full early-to-severe progression.
No. MDMA-assisted therapy is studied for PTSD and psilocybin therapy is studied for depression, each as a standalone treatment with its own dosing and screening protocol. Neither the MAPS MDMA-assisted therapy treatment manual nor published psilocybin trial protocols administer the two substances together.
Disclose every substance you've used or plan to use, including MDMA, psilocybin, other psychedelics, and any prescription or over-the-counter serotonergic medication, plus the timing relative to the planned session and any history of serotonin syndrome or cardiac issues. Clinical trials and reputable retreats generally will not proceed without this disclosure.
Get safety & access research & policy updates
New trials, FDA decisions, and legal changes for safety & access — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.